1型糖尿病中尿白蛋白筛查的最佳频率
研究基于糖尿病控制与并发症试验及其长期随访中1343名参与者的尿白蛋白排泄数据,构建分段指数发病模型,识别个体化筛查方案。与每年筛查相比,个体化筛查使未检出白蛋白尿的时间减少34.9%,检测频率降低20.4%。
要点
- 研究提出基于当前AER和HbA1c的个体化筛查方案:低危者每2年、高危者每6个月、其他每1年筛查。
- 个体化筛查较每年筛查减少34.9%未检出白蛋白尿时间,降低20.4%检测频率。
- 仅按HbA1c或AER单一指标分层,减少幅度较小。
核心结论
- 在1型糖尿病中,个体化替代每年筛查可大幅减少未检出肾病的时间及尿液检测频率。
研究设计与样本
- 利用糖尿病控制与并发症试验及其长期随访中1343名参与者的尿白蛋白排泄测量数据,构建假设6个月恒定风险的分段指数发病模型。
主要发现
- 研究期间任何时间血糖正常后3年白蛋白尿累积发生率为3.2%,与较高的糖化血红蛋白(HbA1c)和AER强烈相关。
- 低风险组(当前AER≤10 mg/24 h且HbA1c≤8%)3年累积发生率为0.6%,建议每2年筛查。
- 高风险组(AER 21-30 mg/24 h或HbA1c≥9%)3年累积发生率为8.9%,建议每6个月筛查。
- 平均风险组(其他)3年累积发生率为2.4%,建议每1年筛查。
- 与每年筛查相比,个体化筛查使未检出白蛋白尿的时间减少34.9%,检测频率降低20.4%。
关键数值与推荐
- 中重度白蛋白尿确诊标准:AER≥30 mg/24 h或≥300 mg/24 h。
- 低风险:当前AER≤10 mg/24 h且HbA1c≤8%,筛查间隔2年。
- 高风险:AER 21-30 mg/24 h或HbA1c≥9%,筛查间隔6个月。
- 平均风险:其他情况,筛查间隔1年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Kidney disease screening recommendations include annual urine testing for albuminuria after 5 years' duration of type 1 diabetes. We aimed to determine a simple, risk factor-based screening schedule that optimizes early detection and testing frequency. RESEARCH DESIGN AND METHODS: Urinary albumin excretion measurements from 1,343 participants in the Diabetes Control and Complications Trial and its long-term follow-up were used to create piecewise-exponential incidence models assuming 6-month constant hazards. Likelihood of the onset of moderately or severely elevated albuminuria (confirmed albumin excretion rate AER ≥30 or ≥300 mg/24 h, respectively) and its risk factors were used to identify individualized screening schedules. Time with undetected albuminuria and number of tests were compared with annual screening. RESULTS: The 3-year cumulative incidence of elevated albuminuria following normoalbuminuria at any time during the study was 3.2%, which was strongly associated with higher glycated hemoglobin (HbA1c) and AER. Personalized screening in 2 years for those with current AER ≤10 mg/24 h and HbA1c ≤8% (low risk [0.6% three-year cumulative incidence]), in 6 months for those with AER 21-30 mg/24 h or HbA1c ≥9% (high risk [8.9% three-year cumulative incidence]), and in 1 year for all others (average risk [2.4% three-year cumulative incidence]) was associated with 34.9% reduction in time with undetected albuminuria and 20.4% reduction in testing frequency as compared with annual screening. Stratification by categories of HbA1c or AER alone was associated with reductions of lesser magnitude. CONCLUSIONS: A personalized alternative to annual screening in type 1 diabetes can substantially reduce both the time with undetected kidney disease and the frequency of urine testing. ARTICLE HIGHLIGHTS: Kidney disease screening recommendations include annual urine testing for albuminuria after 5 years' duration of type 1 diabetes. We investigated simple screening schedules that optimize early detection and testing frequency. Personalized screening in 2 years for those with current AER ≤10 mg/24 h and HbA1c ≤8%, in 6 months for those with AER 21-30 mg/24 h or HbA1c ≥9%, and in 1 year for all others yielded 34.9% reduction in time with undetected albuminuria and 20.4% fewer evaluations compared with annual screening. A personalized alternative to annual screening in type 1 diabetes can substantially reduce both the time with undetected kidney disease and the frequency of urine testing.
引用
- Perkins BA, Bebu I, de Boer IH, et al. Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes. Diabetes Care. 2022. PMID: 36321737. doi:10.2337/dc22-1420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。